TD Asset Management Inc Grows Position in Prime Medicine, Inc. $PRME

TD Asset Management Inc raised its position in Prime Medicine, Inc. (NYSE:PRME) by 690.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 181,048 shares of the company’s stock after purchasing an additional 158,138 shares during the period. TD Asset Management Inc’s holdings in Prime Medicine were worth $1,003,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of PRME. AQR Capital Management LLC grew its position in Prime Medicine by 1,419.4% during the 1st quarter. AQR Capital Management LLC now owns 243,795 shares of the company’s stock worth $485,000 after purchasing an additional 227,749 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Prime Medicine during the first quarter worth about $101,000. Rhumbline Advisers increased its position in Prime Medicine by 13.8% in the 1st quarter. Rhumbline Advisers now owns 81,900 shares of the company’s stock valued at $163,000 after acquiring an additional 9,944 shares during the period. Savant Capital LLC purchased a new stake in Prime Medicine during the 2nd quarter valued at approximately $37,000. Finally, Creative Planning acquired a new stake in Prime Medicine during the 2nd quarter worth approximately $25,000. 70.37% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PRME. Citigroup decreased their price target on Prime Medicine from $5.00 to $4.25 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Lifesci Capital initiated coverage on shares of Prime Medicine in a research note on Tuesday, December 23rd. They issued an “outperform” rating and a $6.00 target price for the company. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Prime Medicine in a report on Monday, November 10th. Finally, Chardan Capital dropped their target price on Prime Medicine from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.21.

Prime Medicine Price Performance

Shares of NYSE:PRME opened at $3.93 on Friday. Prime Medicine, Inc. has a 12 month low of $1.11 and a 12 month high of $6.94. The firm has a market capitalization of $709.41 million, a price-to-earnings ratio of -1.92 and a beta of 2.56. The business’s 50 day simple moving average is $3.82 and its 200-day simple moving average is $4.17.

Prime Medicine News Summary

Here are the key news stories impacting Prime Medicine this week:

• Positive Sentiment: Lifesci Capital reiterated an “Outperform” rating with a $6.00 price target and modeled FY2026 EPS of ($0.90), notably less negative than the current consensus of ($1.68), suggesting expected improvement in the company’s loss profile. Lifesci Capital estimates and rating
• Positive Sentiment: An analyst-consensus summary showed Prime Medicine has an average analyst rating of “Moderate Buy,” which can attract buying interest from funds and retail investors. Prime Medicine receives average “Moderate Buy”
• Neutral Sentiment: Lifesci published granular quarterly EPS forecasts (Q4 2025 and each quarter of 2026 at ~$ (0.23) per quarter) that give investors a clearer guidance baseline for modeling cash needs and runway but don’t change near-term operations. Detailed quarterly EPS estimates
• Negative Sentiment: Despite the upbeat ratings, forecasts still show the company remaining unprofitable next year (negative EPS), underscoring execution and funding risk for a clinical-stage biotech; this keeps downside risk if pipeline progress or financing plans disappoint. Consensus earnings context

About Prime Medicine

Prime Medicine, Inc (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.

Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.